Cardiologist

Board certification
Internal Medicine, Cardiovascular Disease and special board certification in Interventional Cardiology

Education
Cardiologist Steven Heifetz, MD, earned his medical degree from the Medical College of Wisconsin, Milwaukee, Wis. He completed his residency in internal medicine at the University of California, Los Angeles, Calif., and a fellowship in cardiology at the University of Minnesota, Minneapolis, Minn. He is a recognized expert in echocardiography, stress echo and transesophageal echocardigraphy.

Special medical interests
Exercise physiology, heart failure, and angioplasty.

Awards and honors
Named Top Doc in cardiology by Mpls/StPaul magazine, 2004, 2005, 2006, 2007, 2008.

For appointments
952-924-9005

Clinic location
Minnesota Heart Clinic
305 East Nicollet Blvd.
Ridgeview Office Bldg.
Suite 372
Burnsville, MN 55337


Publications
Heifetz SM, Day D, Ipp E.  “Inadvertent Chlorpropamide Hypoglycemia.”  NEJM 316:223, 1987 (Letter).

Kubo SH, Rector TS, Heifetz SM, Cohn JR.  “Role of Alpha II Receptors in Forearm Vasoconstriction in Heart Failure Patients.”  Circ 76:IV-444, 1987 (Abstract).

Heifetz SM, Kubo SH, Finkelstein S, Rector HS, Cohn JN.  “Vascular Compliance Changes During Exercise in Humans.”  Clinical Research, 1989.

Kubo SH, Rector TS, Heifetz SM, Cohn JN.  “Alpha II Receptor Mediated Vaso-constriction in Patients with Congestive Heart Failure.”  Circ 80:1660-1667, 1989.

Heifetz SM, Kubo SH, Rector TS.  “Submaximal Exercise Oxygen Connetics are prolonged in Patients with Heart Failure.”  Clinical Research 37:879A, 1989.

Kubo SH, Williams RE, Rector TS, Heifetz SM.  “Vasodilation Medicated By Endothelial Derived Relaxing Factor in Patients with Chronic Heart Failure.”  Clinical Research 37:929A, 1989.

Bank AJ, Kubo SH, Rector TS, Heifetz SM.  “Forearm Vascular Converting Enzyme Activity in Patients with Heart Failure; Response to Intra-arterial Enalapril.”  Clinical Research 37:872A, 1989.

Kubo S, Rector TS, Heifetz SM, Sato H, Cohn JN.  “Atrial Natriuretic Factor Attenuates Sympathetic Reflexes During Lower Body Negative Pressure in Normal Men.”  Journal of Cardiovascular Pharmacology 16:881-889, 1990.

Bank AJ, Kubo SH, Rector TS, Heifetz SM.  “Local Forearm Vasodilatation with Intra-arterial Administration of Enalapril in Humans.”  Clinical Pharmacology Ther 1991; 50:314-321.

Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM.  “Endothelium Dependent Vasodilatation is Attenuated in Patients with Heart Failure.”  Circulation 1991; 84:1589-1596.

Kubo SH, Rector TS, Williams RE, Bank AJ, Heifetz SM.  “Vasodilation Mediated by Circ Endothelial Derived Relaxing Factor is Reduced in Patients with Heart Failure.” Circulation, 84 (4) 1589-96, 1991.

Heifetz SM. “Cardiac Evaluation of the Spinal Rehabilitation Patient. In: Stude DE, ed. Spinal Rehabilitation Stamford Conn. Appleton & Lange 1999:281-290

Nemec J, Heifetz SM.  “Persistence of Left Supracardinal Vein in an Adult Patient with Heart-Hand Syndrome and Cardiac Pacemaker.”  Congenital Heart Disease 3:219-222, 2008.


Research experience
Principal Investigator of the following clinical trials:

APEX AMI Trial, “Assessment of PEXelizumab in Acute Myocardial Infarction Trial”- 2003-2006

PROFILE Trial, “Prospective Randomized Flosequinan Longevity Evaluation, A Double-Blind, Randomized Placebo-Controlled Study of the Effect of Flosequinan on the Survival of Patients with Chronic CHF”

“A Randomized, Double-Blind, Placebo-Controlled Study of the Chronic Efficacy and Safety of Pimobendan in Patients with Class II-IV Congestive Heart Failure”

OPC-8212, A New Inotropic Agent, (Otsuka Pharmaceutical Company)

Arbutamine Stress Echo Trial

Sub-investigator for the following clinical trials:

PROMISE Trial, “A Randomized, Phase III, Placebo Controlled Survival Study of Oral Milrinone in Patients with Severe Heart Failure”, 1988-1990

“Kerlone ® (betaxolol HCl) Hypertension Clinical Evaluation”, 1990

UNSA Trial, “A Multicenter, Prospective, Randomized, Placebo-Controlled Trial of Activase® and Heparin in Patients with Unstable Angina”, 1989-1990

TOPP Trial, “Thrombolytic Therapy in the Older Patient Population (TTOPP), A Prospective Randomized Placebo Controlled Trial of rt-PA (Activase®) in Patients Over 75 Years of Age”, 1989-1990

SOLVD Trial, “Studies on Left Ventricular Dysfunction”, 1988-1989

CAST Trial, “Cardiac Arrhythmia Suppression Trial”, 1989-1991

GUSTO Trial, “Global Utilization of Streptokinase and t-PA in Occluded Arteries”, 1990-1993

CARS Trial, “Coumadin Aspirin Reinfarction Study”, 1993-1996

GUSTO IIb, “Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes” and “Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Primary PTCA Substudy”, 1994-1995

GUSTO III, The Global Use of Strategies to Open Occluded Coronary Arteries Project: A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) For the Treatment of Acute Myocardial Infarction, 1995-1997.

“A Coronary Stent Pilot Study” for Blue Cross/Blue Shield/Blue Plus of Minnesota, 1995-1996

SYMPHONY Trial, “A Phase III, Multicenter, International, Randomized, Double-blind, Aspirin-controlled Trial to Evaluate the Efficacy and Safety of Sibrafiban (R048-3657), an Oral Platelet Glycoprotein IIB/IIIa Antagonist, a Therapy for the Prevention of Secondary Vascular Events in Patients after and Acute Coronary Syndrome”, 1997 - 1999

InTime II Trial, “Double-blind, Randomized, Multicenter Trial of Single-Bolus Lanoteplase Versus Accelerated Alteplase for the Treatment of Subjects with Acute Myocardial Infarction”, 1997 – 1999

2nd SYMPHONY Trial, “A Phase III, Multicenter, Internataional, Randomized, Double-blind, Aspirin-Controlled Trial to Evaluate the Efficacy and Safety of Two Regimens with Xubix TM (Sibrafiban: Ro 48-3657), an Oral Platelet Glycoprtoein IIb/IIIa Receptor Antagonist, as Therapy for the Long Term Prevention of Secondary Vascular Events in Patients After an Acute Coronary Syndrome”, 1998 - 2000

ALIVE Study: “A Double-Blind, Placebo-Controlled, Parallel Design Study to Determine the Effect of 75mg or 100mg of Orally Administered Azimilide Dihydrochloride versus Placebo on Survival in Recent Post-Myocardial Infarction Patients at Risk of Sudden Death”, 1998 - 2001

AGENT trial, “Phase 1/Phase 2 Study of the Effects of Ascending Doses of Adenovirus Mediated Human FGF-4 Gene Transfer in Patients with Stable Exertional Angina”; 1998 – 2007

AMISTAD II Trial: “A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor?, Adenosine Injection) as an Adjunct to Reperfusion Therapy (Thrombolysis or Mechancial Reperfusion) in the Treatment of Acute Anterolateral Myocardial Infarction” 1999 - 2001

REFLEx Trial, “ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance”, 2004- 2006  

ARRIVE-2 Registry: TAXUS Stent: A Multi-Center Safety Surveillance Program 2004-ongoing

IMPROVE-IT Study: “A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (ezetimibe/simvastatin) vs Simvastatin Monotherapy in High-Risk Patients Presenting with Acute Coronary Syndrome” 2007- ongoing

TRACER Study: “Thrombin Receptor Antagonist for Clinical Event Reduction in ACS: A Multi-center, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with ACS” 2007- ongoing


back